-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651.O1.6 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational I

Symposia: Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Biological therapies, Fundamental Science, Bispecific Antibody Therapy, Translational Research, genomics, bioinformatics, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Plasma Cell Disorders, Diseases, Therapies, immunology, Lymphoid Malignancies, computational biology, Biological Processes, emerging technologies, Technology and Procedures, molecular biology, Study Population, profiling, Human, imaging, Minimal Residual Disease , omics technologies
Saturday, December 10, 2022: 9:30 AM-11:00 AM
R06-R09 (Ernest N. Morial Convention Center)
Moderators:
Francesco Maura, University of Miami and Mehmet K. Samur, PhD, Dana–Farber Cancer Institute, Harvard Medical School
Disclosures:
No relevant conflicts of interest to declare.
9:30 AM

Diana Cortes-Selva1*, Tineke Casneuf, PhD2*, Deeksha Vishwamitra1*, Sarah Stein, PhD1*, Tatiana Perova1*, Sheri Skerget, PhD1*, Elena Ramos3*, Laure van Steenbergen3*, Dries De Maeyer, PhD2*, Rengasamy Boominathan1*, Onsay Lau1*, Cuc Davis, BS1*, Arnob Banerjee1*, Tara Stephenson1*, Clarissa M. Uhlar1*, Rachel Kobos4, Jenna D. Goldberg4*, Lixia Pei4*, Danielle Trancucci4*, Suzette Girgis1, Shun Xin Wang Lin1*, Liviawati S. Wu5*, Philippe Moreau, MD6*, Saad Usmani, MD7, Nizar Jacques Bahlis, MD8, Niels WCJ Van De Donk, MD9 and Raluca Verona1*

1Janssen Research & Development, Spring House, PA
2Janssen Research & Development, Beerse, Belgium
3BioLizard, Ghent, Belgium
4Janssen Research & Development, Raritan, NJ
5Janssen Research & Development, South San Francisco, CA
6University Hospital of Nantes, Nantes, France
7Memorial Sloan Kettering Cancer Center, New York, NY
8Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada
9Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, Netherlands

9:45 AM

Hope Robinson, PhD1*, Nancy Villa, PhD1*, David L. Jaye, MD2, Ajay K. Nooka, MD, MPH, FACP3, Alyssa Duffy4*, Samuel McCachren4*, Julia Manalo1*, Jeffrey M. Switchenko, PhD, MS5*, Ava Horvat6*, Vaunita C Parihar7*, Jingjing Gong8*, Yan Liang, Ph.D.9*, Geoffrey Smith4*, Vikas A Gupta, MD, PhD10*, Lawrence H. Boise, PhD11, Jonathan L. Kaufman, MD12, Craig C Hofmeister, MD13, Nisha Joseph6*, Sagar Lonial, MD13, Kavita Dhodapkar, MD14* and Madhav Dhodapkar, MBBS13

1Hematology/Medical Oncology, Emory University, Atlanta, GA
2Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Dunwoody, GA
3Winship Cancer Institute of Emory University, Atlanta, GA
4Emory University, Atlanta, GA
5Departments of Biostatistics and Bioinformatics, Emory University School of Medicine, Atlanta, GA
6Hematology/Medical Oncology, Emory University, Atlanta
7Cancer Tissue Pathology, Winship Cancer Institute, Atlanta
8NanoString Technologies Inc., Seattle
9Nanostring Technologies Inc., Seattle, WA
10Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
11Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
12Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA
13Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
14Winship Cancer Institute, Emory University, Atlanta

10:00 AM

Camila Guerrero, MSc1,2,3,4*, Noemi Puig, MD, PhD5, Maria Teresa Cedena Romero, MD, PhD6*, Ibai Goicoechea, PhD7, Leire Burgos8*, Diego Alignani, PhD9,10,11*, Aitziber Lopez7*, Sarai Sarvide12*, María José Calasanz, PhD9,13*, Ramon Garcia-Sanz, MD, PhD14, Joaquin Martinez-Lopez, MD PhD15*, Laura Rosiñol, MD, PhD16,17,18*, Esther González Garcia, MD19*, Albert Oriol, MD20,21*, Rafael Rios, MD, PhD22*, Estrella Carrillo-Cruz, MD23*, Marta Sonia Gonzalez Perez, MD24*, Carmen Montes Gaisan, MD25*, Felipe De Arriba, PhD26*, Jose Maria Arguiñano, MD27*, Josep M Marti, MD28*, Yolanda Gonzalez-Montes, MD29*, Antonio Garcia-Guiñon, MD30*, Juan-José Lahuerta, MD, PhD31*, Joan Bladé Creixenti, MD, PhD18, Maria-Victoria Mateos, MD32, Jesús San-Miguel, MD, PhD33 and Bruno Paiva1*

1Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
2Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain
3Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona, Spain
4CIBER-ONC CB16/12/00369, Pamplona, Spain
5Departamento de Hematología, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain
6Hospital 12 de Octubre, Madrid, Spain
7Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Pamplona, Spain
8Centro de Investigación Médica Aplicada, University of Navarra, IDISNA, CIBERONC, Clínica Universidad de Navarra, Pamplona, Spain
9Centro de Investigación Médica Aplicada, University of Navarra, Pamplona, Spain
10Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
11Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
12Centro de Investigación Médica Aplicada, University of Navarra, Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada, Instituto de Investigacion Sanitaria de Navarra (IdiSNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain, Pamplona, Spain
13University of Navarra, Pamplona, Na, ESP
14Hematology Department, University Hospital of Salamanca (HUS/IBSAL), CIBERONC and Cancer Research Institute of Salamanca-IBMCC (USAL-CSIC), Salamanca, Spain
15H12O-CNIO Hematological Malignancies Group, Clinical Research Unit. CNIO, Madrid, Spain
16Hematology Department, Institute of Hematology and Oncology, IDIBAPS, Hospital Clinic, Barcelona, Spain
17Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínico de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain
18Amyloidosis and Myeloma Unit, Hospital Clínic, Barcelona, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
19Hospital de Cabueñes, Gijón, Spain
20Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
21ICO - Hospital Germans Trias I Pujol, Barcelona, Spain
22Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain
23Hematology Department, Hospital Vírgen del Rocío, Instituto de Biomedicina (IBIS / CSIC / CIBERONC), Universidad de Sevilla, Seville, Spain
24Complejo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago De Compostela, ESP
25Hospital Universitario Marqués de Valdecilla, Santander, ESP
26Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
27Complejo Hospitalario de Navarra, Pamplona, Spain
28Hospital Universitari Mútua de Terrassa, Terrassa, Spain
29Institut d’Oncologia Dr. Josep Trueta, Girona, Spain
30Hematology Department, Hospital Arnau de Vilanova, Lleida, Spain
31Hospital Universitario 12 de Octubre; Instituto de Investigación Sanitaria Hospital Universitario 12 de Octubre i+12,H12O-CNIO Haematological Malignancies Clinical Research Unit, Spanish National Cancer Research Centre, Madrid, Spain
32University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
33Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain

10:15 AM

Eileen M Boyle, MD, MSc1, Francesco Maura, MD2, David Coffey, MD3, Kylee H Maclachlan, MBBCh, PhD4, Benjamin Diamond, MD5, Hussein Ghamlouch, PhD1*, Dylan Gagler, MS1*, Patrick Blaney, MS1*, Bachisio Ziccheddu6*, Yubao Wang, PhD1*, Emily Guzman7*, Avital Tenenbaum1*, Ariel Siegel, MD1*, Xiaoyi Chen, MD, PhD1, Gaurav Varma, MD, MSPH1, James E Hoffman, MD8, Dickran Kazandjian, MD3, Hani Hassoun, MD4, Sham Mailankody, MBBS 9, Urvi A Shah, MD4, Carlyn Tan, MD4, Malin Hultcrantz, MD, PhD4, Michael Scordo, MD10, Gunjan L. Shah, MD9, Heather Landau, MD9, David J. Chung, MD, PhD9, Sergio A Giralt, MD11, Yanming Zhang, MD12, Ahmet Dogan, MD, PhD13, Alexander M Lesokhin, MD14, Dennis Verducci3*, Faith E Davies, MD15, Saad Usmani, MD14, Neha Korde, MD16, Ola Landgren, MD17 and Gareth J. Morgan, MD7

1Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY
2Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, PALMETTO BAY, FL
3Myeloma Division, University of Miami, Sylvester Comprehensive Cancer Center, Miami
4Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
5Myeloma Service, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
6Department of Hematology, Univeristy of Miami, Miami, FL
7NYU Langone, Perlmutter Cancer Center, New York
8Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
9Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
10Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center/New York, New York, NY
11Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
12Department of Pathology and Laboratory Medicine, Cytogenetics Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY
13Department of Pathology and Laboratory Medicine, Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY
14Memorial Sloan Kettering Cancer Center, New York, NY
15Perlmutter Cancer Center, NYU Langone Health, New York, NY
16Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY, NY
17Myeloma Division, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL

10:30 AM

Holly Lee1*, Paola Neri, MD, PhD1, Sungwoo Ahn, PhD1*, Ranjan Maity, PhD1*, Noemie Leblay, PhD1*, Bachisio Ziccheddu, PhD2*, Monika Chojnacka, BS2, Rémi Tilmont, MD1*, Elie Barakat, MSc1*, Ola Landgren, MD3, Francesco Maura, MD4 and Nizar Jacques Bahlis, MD1

1Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
2Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL
3Myeloma Division, Department of Medicine, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
4Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, PALMETTO BAY, FL

10:45 AM

Junko Tsuji, PhD1*, Elizabeth D. Lightbody, PhD1,2,3, Romanos Sklavenitis-Pistofidis, MD1,2,3, Michael P. Agius, PhD1,2,3*, Mahshid Rahmat, PhD3*, Hadley Barr, BA2,3*, Yoshinobu Konishi, MD, PhD1,4*, Ankit K. Dutta, PhD2,3*, Nang Kham Su, MSc2,3*, Cody J. Boehner, BS2,3*, Danielle T. Firer, BS1*, Ting Wu, MS1*, Michelle P. Aranha, PhD1,2,3*, Laura Hevenor, BS3*, Erica Horowitz, BA3*, Jacqueline Perry, MPH2,3*, François Aguet, PhD5*, Nicholas J. Haradhvala, PhD1*, Rebecca Boiarsky, MSc1,6*, Gad Getz, PhD1,7* and Irene Ghobrial, MD2,3

1Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA
2Department of Medicine, Harvard Medical School, Boston, MA
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
5Artificial Intelligence Lab, Illumina, Foster City, CA
6CSAIL and IMES, Massachusetts Institute of Technology, Cambridge, MA
7Department of Pathology, Massachusetts General Hospital Cancer Center, Boston, MA

*signifies non-member of ASH